| Effect | None |
| Values | Fibrosis (kPa). Placebo: before 6.52 ± 2.38, after 6.02 ± 1.8. Curcumin: before 6.98 ± 2.42, after 6.2 ± 2.38 |
| Trial Design | Randomized trial |
| Trial Length | 1-6 months |
| Number of Subjects | 52 |
| Gender | Both Genders |
| Age Range | 18-29, 30-44, 45-64, 65+ |
In a randomized, double-blind, placebo-controlled trial, 52 participants with non-alcoholic fatty liver disease were assigned to take 1,500 mg of curcumin (BCM-95) or placebo daily for 12 weeks.
The primary outcome was hepatic steatosis score as assessed through Fibroscan measurements. There was no notable, statistically significant reduction in steatosis or fibrosis compared with placebo. There were also no statistically significant or notable differences in ALT, AST, GGT, HDL, LDL, total cholesterol, fasting glucose, insulin, or insulin sensitivity compared with placebo. There was a modest reduction in triglycerides compared with placebo. However, the difference between groups wasn't statistically significant. There were also no notable or statistically significant differences between groups for weight, body mass index, waist circumference, or hip circumference.
